BRII 296
Alternative Names: BRII-296Latest Information Update: 05 Apr 2024
At a glance
- Originator Brii Biosciences
- Class Antidepressants; Steroids
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Postnatal depression
- Preclinical Major depressive disorder
Most Recent Events
- 13 Mar 2024 Brii Biosciences Limited completes the phase II trial in Postnatal depression (In adults) in USA (IM) (NCT06057012)
- 30 Sep 2023 Phase-II clinical trials in Postnatal depression (In adults) in USA (IM) (NCT06057012)
- 22 Aug 2023 Brii Biosciences plans a phase II trial for Postnatal depression in USA in third quarter of 2023